Stemline Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells


Investor Relations

NASDAQ : STML

$16.28 + 0.26
Volume: 132,500
Dec 18, 2014 4:00 PM ET
Delayed at least 20min., by eSignal.

Stock price graph
     

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics that target both cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinical stage product candidates, SL-401 and SL-701.

SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of a wide range of hematologic cancers. A multicenter clinical trial with SL-401 is currently open and actively accruing patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and relapsed/refractory acute myeloid leukemia (AML). Additional clinical trials with SL-401 are currently open in patients with AML who are in first complete remission (CR) with minimal residual disease (MRD), and in patients with four types of advanced high-risk myeloproliferative neoplasms (MPN), including systemic mastocytosis, advanced symptomatic hypereosinophilic disorder, myelofibrosis, and chronic myelomonocytic leukemia. Previously, SL-401 demonstrated single-agent activity, including multiple durable complete responses (CRs), in a Phase 1/2 trial in several indications including BPDCN and relapsed/refractory AML.

SL-701 is an enhanced immunotherapy designed to activate the immune system to attack tumors. A multicenter clinical trial with SL-701 is currently open for adult patients with glioblastoma multiforme (GBM) in first recurrence. Previously, an earlier version of the therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in adults and children with advanced brain cancers.

Additionally, Stemline has built a robust preclinical pipeline, which includes next generation IL-3R-targeted compounds, SL-501 and SL-101, an innovative discovery platform, and an extensive intellectual property portfolio including some of the earliest patents in the CSC area.



Corporate Snapshot

PDF Corporate Snapshot


Corporate Presentation

PDF Corporate Presentation – December 2014

View all »   RSSRecent Releases

Dec 16, 2014
Stemline Therapeutics Initiates SL-401 Clinical Trial in Four Rare Myeloproliferative Neoplasms

Dec 5, 2014
Stemline Therapeutics Announces Multiple Preclinical Presentations Highlighting Its Pipeline of IL-3R-Directed Therapeutics at the American Society of Hematology (ASH) Annual Meeting


View all »Events & Presentations

There are no upcoming events at this moment.



Copyright 2014 - Stemline Therapeutics, Inc. All rights reserved
Stemline